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Leptin and energy expenditure
Chris J. Hukshorn and Wim H.M. Saris
Purpose of review
A fundamental advance in our understanding of endocrine
control of energy balance and body weight came with the
discovery of the adipocyte-derived hormone leptin. The leptin
pathway appeared to be the long-sought peripheral signal
pathway from the adipose tissue to the brain involved in the
regulation of feeding and energy balance.
Recent findings
Initially, leptin was considered to function as the long-sought
antiobesity hormone. According to this hypothesis, rising
concentrations of leptin with increasing adiposity would
generate a signal to reduce food intake and increase energy
expenditure in order to limit further weight gain. However,
widespread resistance to the proposed antiobesity action of
leptin is observed in humans, which might reflect the fact that
the inability to store energy efficiently at times of abundance is
evolutionarily disadvantageous. According to this alternative
view, falling leptin concentrations observed during fasting act as
a peripheral signal of starvation, which serves to conserve
energy in the face of limited reserves. However, leptin
administration failed to blunt the changes in energy expenditure
during severe energy restrictions in several clinical studies. In
addition, leptin therapy in several different human low-leptin
states failed to affect energy expenditure in recent studies.
Summary
Increasing evidence from human studies suggests that leptin
predominantly influences the human energy balance through
appetite but appears not to be involved in regulating energy
expenditure. None of the expected factors such as resting
metabolic rate, total diurnal energy expenditure or dietary
induced thermogenesis was related to blood leptin
concentrations.
Keywords
appetite, energy expenditure, human, leptin
Curr Opin Clin Nutr Metab Care 7:629–633. # 2004 Lippincott Williams & Wilkins.
Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of
Human Biology, Maastricht University, Maastricht, The Netherlands
Correspondence to C.J. Hukshorn, Department of Human Biology, Maastricht
University, PO Box 616, 6200 MD Maastricht, The Netherlands
Tel: +31 43 388 2112; fax: +31 43 367 0976; e-mail: c.hukshorn@hb.unimaas.nl
Current Opinion in Clinical Nutrition and Metabolic Care 2004, 7:629–633
Abbreviations
PEG-OB pegylated human recombinant leptin
SNS sympathetic nervous system
# 2004 Lippincott Williams & Wilkins
1363-1950
Introduction
The discovery of the hormone leptin (also known as
OB protein) by Zhang and colleagues in December
1994 had an enormous impact both in understanding
the molecular control of energy balance and in attitudes
to the scientific study of obesity [1]. Over the last 9
years more than 4500 papers have been published on
leptin (from the Greek leptos, meaning thin), leading
to an ever-advancing body of knowledge. The leptin
pathway appeared to be the long-sought peripheral
signal pathway from the adipose tissue to the brain
involved in the regulation of feeding and energy
balance.
In 1950, a spontaneous recessive genetic mutation
resulting in profound obesity and diabetes was identi-
fied in an inbred mice colony [2]. Shortly after the
discovery of the ob/ob mouse, additional recessively
inherited forms of obesity, called the diabetes (db/db)
mouse and the Zucker (fa/fa) rat were described [3,4].
Despite being genetically different, these animals
expressed phenotypically identical characteristics, such
as massive obesity of early onset due both to
hyperphagia and reduced energy expenditure. In
addition, these rodents exhibited hypothermia, type 2
diabetes, dyslipidemia, hypercortisolemia, decreased
immune function and infertility due to hypogonado-
tropic hypogonadism. In the 1970s, classic parabiosis
experiments, in which the circulations of ob/ob and db/
db mice were connected, resulted in weight loss due to
hypophagia and finally cachexia and death in the ob/ob
mouse, while retention of increased food intake and
weight in their db/db pair-mates was observed [5,6].
These results led to the hypothesis that the ob gene
encoded a circulating substance that affected the
energy balance and consequently body weight control.
Also, it was suggested that the receptor of this
unknown substance was encoded by, or under control
of, the db gene. It was not until 1994 that this
hypothesis could be verified and a new endocrine
system was revealed.
Leptin, an antiobesity hormone?
Soon after the cloning of the ob gene, leptin-deficient ob/
ob mice were injected with recombinant leptin, which
led to weight loss due to decreased food intake and
increased energy expenditure [1,7–9]. This outcome
supported the original concept that leptin’s function was
to control weight gain by reducing food intake and
increasing energy expenditure as its concentration in
blood rises with increasing adiposity. This impressive
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effect of leptin administration to ob/ob mice raised
expectations that human obesity could also be a
(relative) leptin-deficient state that could possibly be
treated with exogenous leptin. Several early population
studies, however, failed to demonstrate mutations in the
human gene encoding for leptin [10–12]. In contrast,
after the development of radioimmunnoassays for human
leptin, it became clear that in the majority of obese
individuals elevated serum leptin levels are found [13],
which apparently failed to prevent obesity. From these
results, the hypothesis of leptin resistance or reduced
sensitivity to leptin in human obesity emerged, compar-
able to insulin resistance in type 2 diabetes [14,15]. The
observation that higher doses of recombinant leptin are
required to affect feeding behavior, metabolism, and
body fat in diet-induced obese mice compared with
normal mice supported this concept of leptin resistance
[9]. These early results suggested the possibility that
high therapeutical doses of human recombinant leptin
may be able to overcome the presumed increased leptin
resistance present in obese individuals and result in
reduction in body weight by reducing food intake and
increasing energy expenditure.
To test this hypothesis, we studied the effect of weekly
administration of long-acting pegylated human recombi-
nant leptin (PEG-OB) on body weight loss and energy
expenditure in obese men during mild hypocaloric
conditions for 12 weeks. Treatment with PEG-OB
sustained elevated levels of both PEG-OB and endo-
genous leptin and increased post-absorptive satiety
throughout the treatment period without an effect on
weight loss [16]. Despite sustained elevated levels of
both PEG-OB and leptin throughout the treatment
period, no effect was observed on weight loss or energy
expenditure measured by a respiration chamber [17].
This outcome was in line with the results of several
other clinical studies which showed that even supraphy-
siological leptin concentrations failed to significantly
affect body weight in humans during weight main-
tenance or mild hypocaloric conditions [18,19]. In
particular, no effect was observed on energy expenditure
measured by indirect calorimetry [18]. Thus, it is
unlikely that in humans leptin plays a role analogous
to that observed in rodents, in which it is involved in
acute and chronic adaptation of energy intake and
energy expenditure.
Leptin, a starvation hormone?
The outcome of these clinical studies demonstrated that
high leptin concentrations failed to significantly affect
body weight, which implicates that humans are highly
leptin resistant. This observation was, however, consis-
tent with an alternative view of the physiological role of
leptin, which emerged in 1998 [20,21]. The group of
Flier hypothesized that the widespread occurrence of
leptin resistance [22–24] might reflect the fact that the
inability to store energy efficiently at times of abundance
is evolutionarily disadvantageous. These investigators
postulated that the falling concentration of leptin during
starvation and its effects may constitute part of the
thrifty genotype, a set of genes thought to promote
survival during periods of insufficient energy intake in
human evolution by increasing the efficiency of energy
storage. The fact that during starvation leptin levels drop
rapidly and out of proportion to body adiposity changes
appears to support this hypothesis [25,26]. In this
updated thrifty genotype concept, the drop in leptin
concentrations during periods of limited energy intake
might signal the brain to initiate the complex neural,
metabolic, neuroendocrine, and behavioral responses
thought to have survival value in periods of inadequate
energy intake. In addition, this concept suggests that an
effective adipostatic role of leptin would subvert the
thrifty genotype by limiting the capacity of energy
storage during periods of abundance, which would result
in reduced survival in subsequent periods of food
shortages. Stated differently, evolution would favor
resistance to leptin action (leptin resistance) when leptin
concentrations are rising or high during periods of
sufficient energy intake/storage. Furthermore, they
speculated that the shape of the biological dose–
response curve of leptin may depend on the conditions
in which a certain species evolved.
An important clue suggesting that leptin might be
involved in the regulation of the adaptations during
starvation emerged with the observation that leptin-
deficient ob/ob mice possess many characteristics similar
to those during starvation. The genetically obese ob/ob
mouse, which lacks leptin, exhibits all adaptive physio-
logical mechanisms appropriate for food scarcity even
when it has free access to food [21]. The administration
of leptin reversed these adaptations, such as low body
temperature (topor), reductions in thyroid function and
sympathetic nervous system (SNS) activity, hence
raising energy expenditure. A classic replacement study
preventing the characteristic fall in leptin during fasting
blunted the activation of these neuroendocrine axes and
also prevented hypothermia which also increased energy
expenditure [27,28]. However, leptin treatment of
normal mice fed ad libitum only prevents the decrease
in energy expenditure that would normally occur with
the leptin-induced reduction in food intake [29].
An indication suggesting that leptin could play an
important role in the recognition of an early derailment
of energy homeostasis and additional physiological
functions such as reproduction can be derived from
some observational studies in athletes. So far studies
evaluating whether exercise per se or energy deficiency
is the critical factor in the regulation of leptin is limited.
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Van Aggel-Leijssen et al. [30] showed that acute exercise
decreased the nocturnal peak and average 24 h plasma
leptin concentration. Positive or negative energy balance
gave a much higher fluctuation. A short-term training
program (12 weeks) did not influence leptin levels
corrected for changes in fat mass [31]. In a long-term
training program (16 months), however, a significant
inverse relation was found between leptin levels and
hours of training corrected for changes in insulin and
body fat percentage [32]. In an elegant designed study,
Hilton and Loucks [33] dissected the exercise stress
from the energy availability. Low-energy availability
profoundly suppressed the 24 h amplitude of the diurnal
rhythm of leptin when exercise had no effect. The effect
of low-energy availability caused by increased exercise
energy expenditure was smaller than that caused by
dietary restriction. The study demonstrated the impor-
tance of energy availability in comparison to exercise
stress on leptin as an important biomarker of energy
homeostasis.
The hypothesis proposed by Flier et al. provided an
explanation for the ineffectiveness of a high-dose PEG-
OB in our obese individuals on a mild hypocaloric diet
as well for the fairly moderate results of the Heyms-
field trial [19]. Furthermore, an extension of this
hypothesis is that exogenous leptin should affect
energy regulation when administrated during severe
energy restriction. Therefore, to test this hypothesis,
we executed another randomized, double-blind, and
placebo-controlled study to investigate whether ele-
vated leptin levels using PEG-OB affected weight loss,
changes in energy expenditure, and appetite, during
semistarvation induced by a very low calorie diet in
healthy overweight male volunteers. Weekly subcuta-
neous administration of PEG-OB led to significant
additional weight loss and reductions in appetite after 6
weeks of treatment and severe energy restriction, but
did not affect changes in energy expenditure measured
by indirect calorimetry [34 .].
In contrast to rodents, exogenous leptin in our study did
not prevent or blunt the physiological fall in energy
expenditure, which normally occurs during food depriva-
tion. Two major factors reducing energy expenditure
during fasting are the inhibition of SNS activity and the
drop in thyroid hormones. Both fasting-induced effects
were blunted in rodents treated with leptin [27,35].
Moreover, administration of leptin directly into the
brains of rhesus monkeys acutely activated the SNS,
suggesting that leptin may also influence energy
expenditure in these nonhuman primates [36]. The fact
that PEG-OB administration did not disinhibit SNS
activity or prevent the fall in thyroid hormones might
account for the absence of a stimulatory effect on energy
expenditure in this human study [37]. In agreement with
our findings, recombinant replacement therapy during
short-term starvation in healthy men did not significantly
alter the changes in energy expenditure [38 .]. Another
study, however, reported a reversal of the effects of
sustained weight reduction on energy expenditure by a
low dose of exogenous leptin [39].
Leptin replacement in human leptin-
deficiency states
The findings of this study are consistent with the
characteristics of homozygous human patients with total
leptin deficiency or nonfunctional leptin receptors.
These rare and very obese individuals have been shown
to have a normal core temperature and normal resting
energy expenditure but are markedly hyperphagic [40–
43]. In addition, mice heterozygous for the ob gene
[44,45] and individuals who are genetically partially
deficient in leptin [46] appear to be associated with an
intermediate phenotype. Daily subcutaneous human
recombinant leptin treatment of three children with a
mutated ob gene caused rapid and progressive reductions
in body weight. This weight loss was mainly due to
reductions in food intake as a result of decreased
appetite and food-seeking behavior. However, leptin
therapy in two congenital leptin-deficient children failed
to affect basal metabolic rate or free-living energy
expenditure (measured using doubly labeled water)
who were both adjusted for lean body mass [47].
Several other syndromes have been associated with very
low leptin levels. Recently, two siblings with Rabson-
Mendenhall syndrome (severe insulin resistance and
presumed insulin receptor mutations and low leptin
levels) were treated with recombinant human leptin for
10 months. Resting energy expenditure (and lean body
mass) remained stable during leptin treatment [48.].
Leptin-replacement therapy in patients with lipodystro-
phy and very low leptin levels has led to a decrease in
resting metabolic rate most likely secondary to weight
loss [49,50]. A major drawback of some studies, however,
is the fact that the changes in energy expenditure are not
adjusted for changes in lean body mass over the
treatment period.
Conclusion
In summary, in humans, increasing evidence to date
suggests that leptin predominantly influences the human
energy balance through appetite but appears not to be
involved in regulating energy expenditure. Both animal
and human studies indicate that low or falling leptin
levels (as observed during fasting) act as a peripheral
signal of starvation, which subsequently increases
appetite thereby ensuring survival of the species. At
the other end of the spectrum, resistance to the proposed
antiobesity action of high or rising leptin levels is
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observed in both animals and humans. Contrary to
rodents, even supra-physiological leptin concentrations
reached during several clinical trials failed to affect the
human energy balance including energy expenditure.
This widespread occurrence of leptin resistance could
reflect the fact that the inability to store energy
efficiently at times of abundance is evolutionarily
disadvantageous.
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